Daclatasvir (trade name Daklinza) has been approved since August 2014
for the treatment of adults with chronic hepatitis C (CHC) infection.
According to the dossier assessment conducted by the German Institute
for Quality and Efficiency in Health Care (IQWiG) in December 2014, no
added benefit could be derived for daclatasvir.
In an addendum, the Institute now examined
information subsequently submitted by the drug manufacturer in the
commenting procedure: According to the findings, there is a hint of an
added benefit for treatment-naive patients
with genotype 4. The extent is non-quantifiable, however. The study for
patients infected with hepatitis C virus (HCV) of genotype 3, which was
presented for the first time, is unsuitable to derive an added benefit.
Labels: Daklinza® (daclatasvir), genotype 4